Tower Research Capital LLC (TRC) - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 2 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$7,806
-44.8%
39,031
+468.2%
0.00%
Q2 2023$14,150
+48693.1%
6,869
-22.5%
0.00%
-100.0%
Q1 2023$29
+1350.0%
8,862
+739.2%
0.00%
Q4 2022$2
-100.0%
1,056
-81.0%
0.00%
Q2 2022$15,000
+7.1%
5,544
+61.1%
0.00%
Q4 2021$14,000
-68.9%
3,442
-70.8%
0.00%
-100.0%
Q1 2021$45,000
+125.0%
11,805
+171.9%
0.00%0.0%
Q4 2020$20,000
-95.0%
4,342
-81.6%
0.00%
-75.0%
Q3 2020$400,000
+2566.7%
23,632
+1688.9%
0.00%
+300.0%
Q2 2020$15,000
-72.2%
1,321
-88.7%
0.00%
-66.7%
Q1 2020$54,000
+12.5%
11,689
+4.8%
0.00%
-25.0%
Q4 2019$48,000
+2300.0%
11,155
+1640.2%
0.00%
Q3 2019$2,000
-33.3%
641
-6.8%
0.00%
Q3 2018$3,000
-40.0%
688
-50.4%
0.00%
Q2 2018$5,000
+25.0%
1,387
+14.3%
0.00%
Q1 2018$4,000
-33.3%
1,214
-19.3%
0.00%
-100.0%
Q4 2017$6,000
-14.3%
1,504
-16.0%
0.00%0.0%
Q3 2017$7,0001,791
+59600.0%
0.00%
Q3 2016$0
-100.0%
3
-99.7%
0.00%
Q1 2016$3,000
+200.0%
999
+306.1%
0.00%
Q4 2015$1,000
-66.7%
246
-79.8%
0.00%
Q3 2015$3,000
+50.0%
1,217
+156.8%
0.00%
Q2 2015$2,000
+100.0%
474
+273.2%
0.00%
Q1 2015$1,0001270.00%
Q4 2014$000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2023
NameSharesValueWeighting ↓
Acrospire Investment Management LLC 3,586$15,0000.01%
THOMPSON DAVIS & CO., INC. 1,500$6,0000.01%
Psagot Value Holdings Ltd. 39,115$166,0000.01%
GUARDIAN CAPITAL ADVISORS LP 10,000$41,0000.01%
Virtu KCG Holdings LLC 41,537$177,0000.01%
D'Orazio & Associates, Inc. 1,000$4,0000.00%
SIMPLEX TRADING, LLC 7,703$32,0000.00%
NORTHERN TRUST CORP 34,223$145,0000.00%
GROUP ONE TRADING, L.P. 2,180$9,0000.00%
GEODE CAPITAL MANAGEMENT, LLC 73,366$311,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders